Newark, New Castle, USA, May 24, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global dostarlimab-gxly market was conducted by Growth Plus Reports in 2022. The market is expected to hit a ...

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A ...

For patients with primary advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel increases progression-free survival versus carboplatin-paclitaxel alone, according to a ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

The results of a recently disclosed cancer study were "unprecedented" and "unheard-of," and now all eyes are on dostarlimab, the GlaxoSmithKline drug used in the trial to achieve complete remission. A ...

10 Points On Dostarlimab, The Drug That 'Cured' Cancer During Trials As many as 18 rectal cancer patients were given the Dostarlimab drug in prescribed dosages every three weeks for six months.

In the first time in history, a small clinical trial in the United States showed 100% eradication of the cancer disease in patients at the Memorial Sloan Kettering Cancer Center in Manhattan. Although ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

The evaluation committee considered evidence submitted by GSK, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a ...